长春地辛、吡柔比星、环磷酰胺、地塞米松联合治疗非霍奇金淋巴瘤的疗效观察  

Vindesine,Pirarubicin,Cyclophosphamide and Dexamethasone in Tretment of Non-Hodgkin's Lymphoma

作　　者：潘胜美[1] 杨序春[1] 薛宏怡[1] 邱雷[1] 郭勇[1] 高卫安[1] 王辉[1] 

机构地区：[1]舟山市人民医院血液科,浙江舟山316000

出　　处：《中国现代应用药学》2008年第6期547-549,共3页Chinese Journal of Modern Applied Pharmacy

摘　　要：目的观察应用长春地辛(VDS)、吡柔比星(THP)、环磷酰胺(CTX)、地塞米松(DXM)联合治疗非霍奇金淋巴瘤的疗效及不良反应。方法患者予以VDS 2.5 mg.m-2,d1,8;THP 25 mg.m-2,d1,8;CTX 0.6 g.m-2,d1,8;DXM 10 mg.d-1,d1-10。28 d重复,2个疗程予以评价。结果总有效率(CR+PR)为82.1%,不良反应为血液毒性,经G-CSF治疗可恢复,未见明显的外周神经毒性。结论VDS、THP、CTX和DXM联合治疗淋巴瘤安全有效。OBJECTIVE To observe the efficacy and toxicity of vindesine（VDS）,pirarubicin（THP）,cyclophosphamide（CTX） and dexamethasone（DXM） combination therapy for non-Hodgkin＇ s lymphoma. METHODS All palients received VDS 2 mg · m^-2, d1,8;THP 25 mg · m^-2,d1,8 ;CTX 0.6 g · m^-2,d1,8 ;DXM 10 mg · d^-1 ,d1,10. Every, 28-days was one cycle, assessment was given after 2 cycles. RESULTS Overall response rate was 82.1% （ 10 CR and 13 PR）. The main toxicity was hematologic toxicity that could be treated by G-CSF. No significant peripheral neurotoxicity was demonstrated. CONCLUSION Vindesine, pirarubicin, cyclophosphamide and dexamethasone combination therapy for non-Hodgkin＇ s lymphoma is safe and response.

关 键 词：淋巴瘤 长春地辛 吡柔比星 

分 类 号：R969.4[医药卫生—药理学] R979.1[医药卫生—药学]